What assays are planned for future expansion?

Subject to development progress, regulatory approvals, and market priorities, the following expansions are currently planned for the iMOST platform:

• Urine Analysis: Sediment cell analysis and ACR (Albumin-to-Creatinine Ratio)
• Blood Analysis: CRP (via docking station), CD-4 test
• Chemistry panels: kidney, liver, lipid),
• Immunoassay and molecular tests